The supplied records describe separate securities litigation announcements, each setting October 20, 2026, as the deadline for investors seeking appointment as lead plaintiff. The Fractyl Health, Inc. action alleges that the company misrepresented Revita’s effectiveness and the reliability of REMAIN-1 Midpoint Cohort results during a class period from January 13, 2025, through January 29, 2026. The Taboola.com Ltd. action covers securities purchased from May 6 through August 4, 2026, and alleges that Taboola concealed increasing low-quality publisher relationships, the earnings effects of ending those relationships and an overstatement of their value. Taboola reported second-quarter 2026 revenue of $476.8 million, below guidance of $492 million to $505 million, lowered its full-year revenue and gross-profit outlooks, and saw its shares fall 27.41% to $3.84 on August 5, 2026. Rosen Law Firm issued a Sept. 16 reminder that the Taboola lawsuit has been filed, while stating that no class has yet been certified.